tiprankstipranks
Morphosys AG (DE:MOR)
XETRA:MOR

Morphosys (MOR) Stock Price & Analysis

8 Followers

MOR Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€14.52 - €68.00
Previous Close€67.7
Volume42.40K
Average Volume (3M)447.15K
Market Cap
€2.55B
Enterprise Value€2.65B
Total Cash (Recent Filing)$158.50M
Total Debt (Recent Filing)$256.45M
Price to Earnings (P/E)-11.9
Beta0.62
Apr 29, 2024
-€0.31
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.68
Shares Outstanding34,160,673
10 Day Avg. Volume636,174
30 Day Avg. Volume447,154
Standard Deviation0.17
R-Squared0.02
Alpha0.00787
Financial Highlights & Ratios
Price to Book (P/B)-0.73
Price to Sales (P/S)10.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.05
Enterprise Value/Gross Profit14.70
Enterprise Value/Ebitda-389.30
Forecast
Price Target Upside-23.19% Downside
Rating ConsensusHold
Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say
Acquisition And Strategic PositioningThe expected closure of the acquisition by Novartis could enhance regulatory efficiency and bolster the company's strategic market position.
Financial StabilityThe company has reported ample cash reserves, projected to sustain its operations into the foreseeable future, underpinning financial stability.
Product Pipeline DevelopmentProgress in the company's product pipeline is evident as plans to seek regulatory approvals for the innovative drug pelabresib have been set in motion.
Bears Say
Drug DevelopmentPelabresib did not achieve a key secondary endpoint of TSS in its pivotal trial and failed to show benefit in advanced patients.
Financial PerformanceMonjuvi sales rights were outlicensed to INCY, leading to a reduction in the company's fundamental value.
Mergers And AcquisitionsThe deal may have more anti-trust risks than are apparent at first glance, which could hinder the acquisition process.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

1.54%4.39%4.74%89.32%
4.74% Other Institutional Investors
89.32% Public Companies and
Individual Investors

MOR FAQ

What was Morphosys AG’s price range in the past 12 months?
Morphosys AG lowest stock price was €14.52 and its highest was €68.00 in the past 12 months.
    What is Morphosys AG’s market cap?
    Currently, no data Available
    When is Morphosys AG’s upcoming earnings report date?
    Morphosys AG’s upcoming earnings report date is Apr 29, 2024 which is in 6 days.
      How were Morphosys AG’s earnings last quarter?
      Morphosys AG released its earnings results on Mar 13, 2024. The company reported €1.43 earnings per share for the quarter, beating the consensus estimate of -€1.878 by €3.308.
        Is Morphosys AG overvalued?
        According to Wall Street analysts Morphosys AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Morphosys AG pay dividends?
          Morphosys AG does not currently pay dividends.
          What is Morphosys AG’s EPS estimate?
          Morphosys AG’s EPS estimate is -€0.31.
            How many shares outstanding does Morphosys AG have?
            Morphosys AG has 37,716,423 shares outstanding.
              What happened to Morphosys AG’s price movement after its last earnings report?
              Morphosys AG reported an EPS of €1.43 in its last earnings report, beating expectations of -€1.878. Following the earnings report the stock price went down -0.392%.
                Which hedge fund is a major shareholder of Morphosys AG?
                Currently, no hedge funds are holding shares in DE:MOR
                ---

                Morphosys Stock Smart Score

                7
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Morphosys AG

                MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.
                ---

                MOR Stock 12 Months Forecast

                Average Price Target

                €52.00
                ▼(-23.19% Downside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","69":"€69","30.75":"€30.8","43.5":"€43.5","56.25":"€56.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,30.75,43.5,56.25,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.05,67.12307692307692,67.19615384615385,67.26923076923077,67.34230769230768,67.41538461538461,67.48846153846154,67.56153846153846,67.63461538461539,67.70769230769231,67.78076923076922,67.85384615384615,67.92692307692307,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.05,65.8923076923077,64.73461538461538,63.57692307692307,62.419230769230765,61.26153846153846,60.10384615384615,58.94615384615385,57.78846153846153,56.63076923076923,55.47307692307692,54.315384615384616,53.15769230769231,{"y":52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.05,63.815384615384616,60.58076923076923,57.34615384615385,54.11153846153846,50.87692307692308,47.642307692307696,44.40769230769231,41.17307692307692,37.93846153846154,34.70384615384616,31.46923076923077,28.234615384615388,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.015,"date":1681430400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1683244800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.45,"date":1685664000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.03,"date":1688688000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.97,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.89,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.48,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":30.41,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.44,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.43,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.16,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":67.05,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                BioNTech SE
                CureVac
                Formycon AG
                Immatics
                Affimed

                Best Analysts Covering MOR

                1 Year
                James GordonJ.P. Morgan
                1 Year Success Rate
                15/32 ratings generated profit
                47%
                1 Year Average Return
                +14.08%
                reiterated a buy rating 3 months ago
                Copying James Gordon's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +14.08% per trade.
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis